Pet Cancer Therapeutics Market Report 2026

The pet cancer therapeutics market size has grown rapidly in recent years. It will grow from $0.43 billion in 2025 to $0.48 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to rising incidence of cancer in companion animals, development of conventional chemotherapy protocols, increasing veterinary hospital infrastructure, advancements in diagnostic imaging for pets, growth of companion animal population.

The pet cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $0.72 billion in 2030 at a compound annual growth rate (CAGR) of 11%. The growth in the forecast period can be attributed to advancements in immunotherapy and targeted therapy, integration of artificial intelligence in diagnosis and treatment, expansion of online and retail pharmacy channels, increasing awareness of early cancer detection, rising investment in veterinary oncology research. Major trends in the forecast period include rising adoption of targeted therapies for pet cancer, increasing use of immunotherapy in companion animals, expansion of multi-modal cancer treatment protocols, growing focus on early cancer detection in pets, integration of palliative care in pet oncology.

The rising prevalence of pet cancer is expected to drive the growth of the pet cancer therapeutics market in the coming years. Pet cancer refers to the abnormal and uncontrolled growth of cells in domesticated animals, such as dogs or cats, leading to tumor formation. The increase in pet cancer cases is primarily attributed to exposure to environmental toxins and pollutants, along with genetic and lifestyle factors, resulting in higher demand for advanced and effective cancer therapeutics for pets. Pet cancer therapeutics work by targeting and destroying cancer cells or slowing tumor growth, thereby improving survival outcomes and reducing pain and discomfort in affected animals. For example, in 2025, according to the American Veterinary Medical Association (AVMA), a US-based veterinary health authority, approximately 1 in 4 dogs will develop cancer during their lifetime, with the risk rising to 1 in 2 for dogs over 10 years of age. Consequently, the increasing prevalence of pet cancer is expected to fuel growth in the pet cancer therapeutics market.

Leading companies in the pet cancer therapeutics market are focusing on developing epigenetic technologies to enhance the efficacy of treatments and improve precision in targeting cancer cells, ultimately leading to better outcomes for pets diagnosed with cancer. Epigenetic technology involves techniques that modify gene expression without altering the underlying DNA sequence, thereby influencing cellular behavior and therapeutic results. For example, in April 2024, VolitionRx Limited, a US-based multinational epigenetics company, launched the Nu.Q Vet Cancer Test. This test operates on the Element i+ Analyzer and delivers rapid results - typically within approximately six minutes. It employs an enzyme-linked immunosorbent assay to detect circulating nucleosomes in the blood, which can serve as indicators of cancer presence.

In June 2024, Lantheus, a US-based company specializing in the development and commercialization of innovative imaging products and radiopharmaceuticals for diagnostic purposes in healthcare, acquired Life Molecular Imaging GmbH for an undisclosed sum. This acquisition is intended to enhance Lantheus's portfolio of diagnostic imaging solutions, expand its capabilities in molecular imaging, and strengthen its position within the healthcare market. Life Molecular Imaging GmbH, based in Germany, is dedicated to advancing imaging technologies, particularly in the realm of molecular imaging.

Major companies operating in the pet cancer therapeutics market are AB Science, Elanco Animal Health, ELIAS Animal Health, Zoetis Inc., Anivive Lifesciences Inc., QBiotics Group Ltd., Regeneus Ltd., VetDC Inc., PetCure Oncology at Veterinary Radiosurgery and Imaging Center, Torigen Pharmaceuticals Inc., Dechra Pharmaceuticals plc, AdvaVet Inc., Oasmia Pharmaceuticals AB, Sumitomo Pharma Animal Health Co., Vetivax, CarthroniX Inc., Boehringer Ingelheim GmbH, Nippon Zenyaku Kogyo Co. Ltd., Vivesto AB, Norbrook Laboratories Ltd., Zenoaq Co. Ltd., Morphogenesis Inc.

North America was the largest region in the pet cancer therapeutics market in 2025. The regions covered in the pet cancer therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pet cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the pet cancer therapeutics market by increasing the cost of imported oncology drugs, targeted therapy agents, and specialized diagnostic equipment, particularly impacting regions such as North America and Europe. Segments like immunotherapy and advanced radiation therapies are most affected. Positive outcomes include incentivizing domestic production of therapeutics and promoting localized research initiatives to reduce dependency on imports.

The pet cancer therapeutics market research report is one of a series of new reports that provides pet cancer therapeutics market statistics, including pet cancer therapeutics industry global market size, regional shares, competitors with a pet cancer therapeutics market share, detailed pet cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the pet cancer therapeutics industry. This pet cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pet cancer therapeutics involve the use of various treatments and medications to manage or cure cancer in pets. The choice of therapeutics depends on several factors such as the type and stage of cancer, as well as the pet's age and overall health.

The main types of pet cancer therapeutics are tailored to specific cancer types, including melanoma, mast cell cancer, lymphoma, and mammary and squamous cell cancer. Melanoma is a type of cancer that originates from pigment-producing cells called melanocytes. These therapeutics can be administered through various routes, including oral and injection methods, tailored for dogs, cats, and other animals. Different therapies employed in pet cancer treatment include chemotherapy, radiation therapy, immunotherapy, tomo therapy, and others. These therapies are utilized by veterinary hospitals, clinical pharmacies, retail pharmacies, online pharmacies, and other healthcare facilities focused on pet health.

The pet cancer therapeutics market consists of revenues earned by entities by surgery and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.